Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics regarding potential violations of federal securities laws related to misleading statements about the safety and commercial prospects of its drug candidate DCCR (VYKAT XR) [1][3]. Group 1: Investigation Details - The investigation focuses on whether Soleno and its executives made materially false and misleading statements about DCCR, particularly regarding its safety profile and clinical results [1][3]. - A federal securities fraud class action complaint has been filed, alleging that Soleno misrepresented DCCR's safety and efficacy, leading to significant stock price declines [3][7]. Group 2: Stock Performance and Impact - Following disclosures about the risks associated with DCCR, Soleno's stock price fell from a high of over $90 per share to below $45 per share, resulting in substantial losses for investors [3][7]. - The controversy surrounding DCCR has disrupted its commercial launch and negatively impacted physician adoption [7]. Group 3: Safety Concerns - Significant safety concerns regarding DCCR were allegedly downplayed or concealed, including evidence of excess fluid retention in clinical trial participants [7]. - Reports indicated that the integrity of Soleno's clinical trial data was questioned, and there were serious adverse safety events associated with the drug [7].